A phenylalanine dehydrogenase mutant and its application in the synthesis of L-unnatural amino acids

By mutation of phenylalanine dehydrogenase at specific sites, forming thermally stable and stable mutants under partial alkaline conditions, the existing amino acid dehydrogenase has solved the low catalytic vitality and substrate spectrum of existing amino acid dehydrogenases in non-natural substrates. The narrow problem has achieved efficient and high optical purity of non-natural amino acid synthesis, suitable for industrial applications.

CN117844773BActive Publication Date: 2024-11-15JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410213255.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-27
Publication Date
2024-11-15
Estimated Expiration
2044-02-27

AI Technical Summary

Technical Problem

The existing amino acid dehydrogenases have low catalytic activity in non-natural substrates and have a narrow substrate spectrum, and poor stability under partially alkaline conditions, resulting in challenges in the chiral amine synthesis process.

Method used

By mutation of specific amino acid sites of phenylalanine dehydrogenase, a phenylalanine dehydrogenase mutant with high thermal stability and stable under alkaline conditions can be efficiently asymmetrically reduced aminating α -Ketoacid substrate, broadening the catalytic substrate spectrum.

Benefits of technology

The mutant significantly improved the amination specific vitality, the optical purity (ee value) of the product reached 99.9%, remained stable in a relatively alkaline environment, was suitable for non-natural amino acid synthesis, mild reaction conditions, and was suitable for industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117844773B_ABST
    Figure CN117844773B_ABST
Patent Text Reader

Abstract

The invention discloses a phenylalanine dehydrogenase mutant and its application in the synthesis of L non-natural amino acids, belonging to the technical field of enzyme engineering and microbial engineering. The phenylalanine dehydrogenase mutant provided by the present invention can asymmetric reduction amination of α-keto acid substrates 2-(naphthalene-1-yl)-2-oxoacetic acid, 2-(naphthalene-2-yl)-2-oxoacetic acid, 3-(naphthalene-1-yl)-2-oxopropionic acid, 3-(naphthalene-2-yl)-2-oxopropionic acid, wherein the four mutants V329G / S176G / L326M / T144I can efficiently synthesize (S)-2-amino-2-(naphthalene-1-yl)acetic acid, and the conversion rate can reach 99.84% when the reaction time is 10h, and the reaction conditions are mild, environmentally friendly, easy to operate, and easy to industrial amplification. Therefore, the phenylalanine dehydrogenase mutant of the present invention has a good prospect for industrial application development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical fields of enzyme engineering and microbial engineering, in particular to a phenylalanine dehydrogenase mutant and application thereof in synthesizing L-unnatural amino acids. Background Art

[0002] Amino acids and amino acid derivatives are very important pharmaceutical intermediates and have very broad application prospects in pharmaceutical research. It is estimated that about 40% of chiral drugs on the market currently contain chiral amine building blocks, such as anti-inflammatory drugs, anti-Alzheimer's drugs, antidepressants, anti-AIDS drugs, etc. Chiral amines occupy an important position in the pharmaceutical field. Due to the importance and great value of chiral amines in the synthesis of drug molecules, the research and development of their synthesis technology has become a research hotspot in the field of new drug development.

[0003] Although the synthesis of chiral amines has received increasing attention in the past few decades, it is still challenging to achieve simple and efficient synthesis of specific chiral amines. Classical chemical methods for synthesizing chiral amines include racemate resolution and asymmetric transformation of potential chiral compounds. The theoretical yield of the asymmetric resolution method is only 50%. The latter involves asymmetric hydrogenation of imines or enamines, enantioselective CH bond amination, asymmetric reductive amination, asymmetric nucleophilic addition of C=N double bonds, and asymmetric hydrogen amination. There are problems such as harsh reaction conditions, the use of toxic and harmful chemical reagents such as transition metals, cumbersome reaction operation process, and low enantioselectivity. Compared with chemical methods, biocatalysis has the advantages of mild reaction conditions, high selectivity, and environmental friendliness. It has been widely used in the industrial production of pharmaceutical intermediates, agricultural chemicals, fine chemicals, and other products. At present, a variety of biocatalysts have been successfully used in the synthesis of chiral amines, including hydrolases, amino acid dehydrogenases, transaminases, amine oxidases, imine reductases, reductive amination enzymes, ammonia lyases, amine dehydrogenases, etc.

[0004] Amino acid dehydrogenase (AADH) can use inorganic ammonium or organic amine as amine donor, and NADH as reducing force to synthesize chiral amino acids and chiral amines through asymmetric reductive amination. The only byproduct is water, and the product has high selectivity, single configuration, and high atomic utilization rate. It conforms to the purpose of green chemistry and has high development and application value. Among the many amino acid dehydrogenases, phenylalanine dehydrogenase (PheDH) is a type of amino acid dehydrogenase that uses phenylpyruvate (amination) and phenylalanine (deamination) as natural substrates and NADH (amination) / NAD+ (deamination) as coenzymes. Phenylalanine dehydrogenase has a wide range of applications in the synthesis of phenylalanine and aromatic amino acids and amino acid derivatives, such as the synthesis of important non-natural amino acids such as L-phenylglycine, L-homophenylalanine, and 2-(3-hydroxy-1-adamantyl)-(2S)-aminoglycolic acid (for details, see references "Cheng, et al., RSC Adv., 2016, 6, 80557-80563", "Wu, et al., Biotechnol Biofuels, 2021, 14, 207", "RL, et al, Adv. Synth. Catal. 2007, 349, 1369-1378").

[0005] Although amino acid dehydrogenase has shown great potential, it still has problems such as low catalytic activity for non-natural substrates and narrow substrate spectrum. In addition, the enzyme is poorly stable under alkaline conditions, and the reaction process of using amino acid dehydrogenase to prepare chiral amines also needs further development and optimization. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a phenylalanine dehydrogenase mutant with good thermal stability and good stability under alkaline conditions. The mutant is obtained by mutating the 329th valine, the 176th serine, the 144th threonine and the 326th leucine of the phenylalanine dehydrogenase with SEQ ID NO.1 as the starting sequence. The obtained phenylalanine mutant can asymmetrically reduce and aminize α-keto acid substrates and can be used to prepare L-non-natural amino acids.

[0007] The first object of the present invention is to provide a phenylalanine dehydrogenase mutant, which is obtained by subjecting the starting sequence of the amino acid sequence as shown in SEQ ID NO.1 to any of the following modifications:

[0008] (1) Valine at position 329 was mutated to glycine;

[0009] (2) Valine at position 329 mutated to glycine, and serine at position 176 mutated to glycine or alanine;

[0010] (3) Valine at position 329 mutated to glycine, serine at position 176 mutated to glycine, and threonine at position 144 mutated to valine, leucine, isoleucine, or methionine;

[0011] (4) Valine at position 329 mutated to glycine, serine at position 176 mutated to glycine, and leucine at position 326 mutated to valine, serine, cysteine, or methionine;

[0012] (5) Valine at position 329 mutated to glycine, serine at position 176 mutated to glycine, leucine at position 326 mutated to methionine, and threonine at position 144 mutated to methionine or isoleucine;

[0013] (6) The valine at position 329 mutated to glycine, the serine at position 176 mutated to glycine, the leucine at position 326 mutated to cysteine, and the threonine at position 144 mutated to methionine or isoleucine.

[0014] The second object of the present invention is to provide a gene encoding the above-mentioned phenylalanine dehydrogenase mutant.

[0015] The third object of the present invention is to provide a recombinant expression vector comprising the above gene.

[0016] Furthermore, the expression vector is pET-28a(+) plasmid, pET-28b(+) plasmid or pET-20b(+) plasmid.

[0017] The fourth object of the present invention is to provide a host cell comprising the above phenylalanine dehydrogenase mutant.

[0018] A fifth object of the present invention is to provide use of the above-mentioned phenylalanine dehydrogenase mutant, the above-mentioned gene, the above-mentioned recombinant expression vector or the above-mentioned host cell in the production of L-non-natural amino acids.

[0019] The sixth object of the present invention is to provide a method for producing L-unnatural amino acids, comprising the following steps: adding the above-mentioned phenylalanine dehydrogenase mutant or an expression system containing the mutant to a reaction system containing a substrate for reaction.

[0020] Furthermore, the reaction system contains coenzymes and a coenzyme circulation system.

[0021] Furthermore, the coenzyme circulation system is any one of D-glucose and glucose dehydrogenase, phosphite and phosphite dehydrogenase, formate and formate dehydrogenase, lactate and lactate dehydrogenase, glycerol and glycerol dehydrogenase.

[0022] Furthermore, the reaction system contains D-glucose and glucose dehydrogenase.

[0023] Further, the substrate includes one or more of 2-(naphthalene-1-yl)-2-oxoacetic acid, 2-(naphthalene-2-yl)-2-oxoacetic acid, 3-(naphthalene-1-yl)-2-oxopropionic acid, and 3-(naphthalene-2-yl)-2-oxopropionic acid.

[0024] Compared with the prior art, the above technical solution of the present invention has the following technical effects:

[0025] The phenylalanine dehydrogenase mutant provided by the present invention can synthesize L-non-natural amino acids through efficient asymmetric amination of α-keto acid substrates, and has greatly improved amination specific activity compared with the wild type, and the product ee value can reach 99.9%, wherein the conversion rate of the four mutants V329G / S176G / L326M / T144I in synthesizing (S)-2-amino-2-(naphthalene-1-yl)acetic acid reaches 99.84% when the reaction time is 10 hours, and the three mutants V329G / S176G / T144V and V329G / S176G / T144M can catalyze four different types of α-keto acid substrates, greatly broadening the catalytic substrate spectrum of phenylalanine dehydrogenase. The phenylalanine dehydrogenase mutant obtained by the present invention has high thermal stability and good stability in a partial alkaline environment, is applied to the field of non-natural amino acid synthesis, has mild reaction conditions, is environmentally friendly, is simple to operate, is easy to industrially scale up, and has good industrial application development prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein

[0027] Figure 1 is the electrophoresis pattern of PCR amplification of the recombinant plasmid in Example 1 of the present invention, wherein M is a marker, and different lanes correspond to mutants M1-M3.6 in Table 1;

[0028] Figure 2 is the PCR extended electrophoresis pattern of the recombinant plasmid in Example 1 of the present invention, wherein M is a marker, and different lanes correspond to mutants M3.7-M4.4 in Table 1;

[0029] Figure 3 It is the SDS-PAGE electrophoresis analysis result of the expression product obtained by the shake flask induced fermentation of the recombinant Escherichia coli in Example 1 of the present invention; wherein the lanes are Marker, flow-through, 50mM, 100mM, 150mM, 200mM, 250mM, 300mM imidazole collection solution in sequence;

[0030] Figure 4 It is the chiral chromatogram of the product (S)-2-amino-2-(naphthalene-1-yl)acetic acid / (R)-2-amino-2-(naphthalene-1-yl)acetic acid in Example 3 of the present invention.

[0031] Figure 5 is a diagram showing the conversion process of the product obtained by asymmetric reductive amination of α-keto acid 2-(naphthalen-1-yl)-2-oxoacetic acid by mutant M4.2 in Example 3 of the present invention;

[0032] Figure 6 Schematic diagram of asymmetric reduction of phenylalanine dehydrogenase mutants. DETAILED DESCRIPTION

[0033] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0034] The Escherichia coli E. coli BL21 (DE3) involved in the examples was purchased from Beina Biotechnology; the pET-28a (+) plasmid and NADH involved in the following examples were purchased from Novagen; the glucose dehydrogenase (GDH) and lactate dehydrogenase (LDH) involved in the following examples were purchased from Novagen; the D-glucose involved in the following examples was purchased from Jierui; the α-keto acid substrate involved in the following examples was purchased from Shanghai Bioengineering Co., Ltd. (the above-mentioned strain Escherichia coli E. coli BL21 (DE3) can be purchased and does not need to be deposited for patent procedures).

[0035] The culture medium involved in the embodiment is as follows:

[0036] LB liquid culture medium: yeast powder 5.0 g / L, tryptone 10.0 g / L, NaCl 10.0 g / L, kanamycin 100 mg / L.

[0037] LB solid medium: yeast powder 5.0 g / L, tryptone 10.0 g / L, NaCl 10.0 g / L, agar powder 15 g / L, kanamycin 50 mg / L.

[0038] The detection method of phenylalanine dehydrogenase activity is as follows:

[0039] After keeping 200 μL of NH4Cl / NH4OH buffer (2M, pH 9.0) containing 4 mM NADH and 2.0 mM α-keto acid substrate at 30°C for 2 min, 10 μL of pure enzyme solution was added to the above buffer and reacted at 30°C for 30 min. 20 μL of 6 M concentrated hydrochloric acid was added to terminate the reaction. The amount of product generated was determined by HPLC, and the enzyme activity was calculated based on this.

[0040] The calculation formula of enzyme activity is as follows:

[0041] Enzyme activity (U / mg) = (C1×V1)×103 / (T×C2×V2);

[0042] Where, C1 is the concentration of the generated product, in mol / L; V1 is the volume of the reaction solution, in mL; C2 is the protein concentration of the enzyme, in mg / ml; V2 is the volume of the enzyme added to the reaction system, in μL; T is the reaction time, in min;

[0043] Definition of enzyme activity: Under these conditions, the amount of enzyme required to catalyze the oxidation of 1 μmol of substrate to produce 1 μmol of product per minute is one enzyme activity unit (1U).

[0044] The method for detecting the conversion efficiency and stereoselectivity of the asymmetric reductive amination of α-keto acids 2-(naphthalene-1-yl)-2-oxoacetic acid and 2-(naphthalene-2-yl)-2-oxoacetic acid by phenylalanine dehydrogenase is as follows:

[0045] After 200 μL of NH4Cl / NH4OH buffer (2M, pH 9.0) containing 4 mM NADH and 2.0 mM α-keto acid substrate was incubated at 30°C for 2 min, 10 μL of pure enzyme solution was added to the above buffer and reacted at 30°C for 30 min. 20 μL of 6 M concentrated hydrochloric acid was added to terminate the reaction, and chiral liquid chromatography was performed to analyze the conversion efficiency and ee value;

[0046] The conversion efficiency chromatographic conditions are as follows: ZORBAX SB-Aq (5 μm, 250 mm×4.6 mm) liquid chromatography column, mobile phase acetonitrile: 20 mM potassium dihydrogen phosphate (20:80, v / v), flow rate 1 mL / min, column temperature 35°C, UV detection wavelength 280 nm, injection volume 5 μL, the retention times of substrate 2-(naphthalene-1-yl)-2-oxoacetic acid and product (S)-2-amino-2-(naphthalene-1-yl)acetic acid are 4.12 min and 10.71 min, respectively; the retention times of substrate 2-(naphthalene-2-yl)-2-oxoacetic acid and product (S)-2-amino-2-(naphthalene-2-yl)acetic acid are 4.02 min and 10.51 min, respectively;

[0047] The stereoselective chromatographic conditions are as follows: Astec CHIROBIOTICTM T (15 cm×4.6 mm, 5 μm) liquid chromatography column, mobile phase of methanol:water (60:40, v / v), flow rate 0.6 mL / min, column temperature 35°C, UV detection wavelength 280 nm, injection volume 5 μL, retention times of (S)-2-amino-2-(naphthalen-1-yl)acetic acid and (R)-2-amino-2-(naphthalen-1-yl)acetic acid are 3.82 min and 7.01 min, respectively; retention times of (S)-2-amino-2-(naphthalen-2-yl)acetic acid and (R)-2-amino-2-(naphthalen-1-yl)acetic acid are 4.22 min and 8.91 min, respectively.

[0048] The conversion efficiency is calculated as follows:

[0049]

[0050] The calculation method of ee value is as follows:

[0051]

[0052]

[0053] As is defined as: the molar concentration of (S)-2-amino-2-(naphthalene-1-yl)acetic acid in the reaction solution; A R Defined as: the molar concentration of (R)-2-amino-2-(naphthalene-1-yl)acetic acid in the reaction solution; A sub Defined as: the molar concentration of unreacted 2-(naphthalen-1-yl)-2-oxoacetic acid in the reaction solution.

[0054] Example 1: Preparation, expression and purification of phenylalanine dehydrogenase mutants

[0055] A gene encoding phenylalanine dehydrogenase having an amino acid sequence as shown in SEQ ID NO.1 was chemically synthesized (the nucleotide sequence of the gene was shown in SEQ ID NO.2), the obtained gene was ligated with a pET-28a(+) plasmid after double restriction digestion (Nde I and Xho I), the ligation product was transformed into Escherichia coli E. coli BL21 (DE3), the transformation product was spread on an LB solid medium, and cultured at 37° C. for 8-10 h, 5 transformants were picked on the LB solid medium, inoculated into an LB liquid medium for culture, and the plasmid was extracted after cultured at 37° C. for 10 h, and the extracted plasmid was subjected to restriction digestion verification and sequencing verification. If the verification was correct, a recombinant plasmid pET28a-QtPheDH containing a gene encoding a wild-type phenylalanine dehydrogenase and a recombinant bacterium E. coli BL21 / pET28a-QtPheDH containing a gene encoding a wild-type phenylalanine dehydrogenase were obtained.

[0056] The whole plasmid PCR technique was used to perform site-directed mutagenesis using the obtained recombinant plasmid pET28a-QtPheDH as a template to obtain the phenylalanine dehydrogenase mutants V329G (Valine at position 329 mutated to Glycine), S176G (Serine at position 176 mutated to Glycine), S176A (Serine at position 176 mutated to Alanine), L326S (Leucine at position 326 mutated to Serine), L326V (Leucine at position 326 mutated to Valine), L326C (Leucine at position 326 mutated to Cysteine), L326M (Leucine at position 326 mutated to Methionine), T144I (Threonine at position 144 mutated to Isoleucine), T144M (Threonine at position 144 mutated to Methionine), and T144V (Threonine at position 144 mutated to Valine). The mutation sites and numbers of the mutants are shown in the following table.

[0057] Table 1 Mutation sites and numbers

[0058]

[0059]

[0060] Among them, the primers used for mutations V329G, S176G, S176A, L326C, L326M, T144I, and T144M are as follows:

[0061] V329G-F: 5'-GGTTTGATCCAGggtGCGGACGAA-3' (SEQ ID NO.3)

[0062] V329G-R: 5'-CAGTTCGTCCGCaccCTGGATCAA-3' (SEQ ID NO.4)

[0063] S176G-F: 5'-GGAGGCGGAGACggtTCCGTTCCG-3' (SEQ ID NO.5)

[0064] S176G-R: 5'-GGTCGGAACGGAaccGTCTCCGCC-3' (SEQ ID NO.6)

[0065] S176A-F: 5'-GGAGGCGGAGACgcaTCCGTTCCG-3' (SEQ ID NO.7)

[0066] S176A-R: 5'-GGTCGGAACGGAtgcGTCTCCGCC-3' (SEQ ID NO.8)

[0067] L326C-F: 5'-AACGCGGGGGGTtgtATCCAGGGT-3' (SEQ ID NO.9)

[0068] L326C-R: 5'-CGCACCCTGGATacaACCCCCCGC-3' (SEQ ID NO.10)

[0069] L326M-F: 5'-AACGCGGGGGGTatgATCCAGGGT-3' (SEQ ID NO.11)

[0070] L326M-R: 5'-CGCACCCTGGATcatACCCCCCGC-3'(SEQ ID NO.12)

[0071] T144I-F: 5'-TTCTATACAGGAattGATATGGGC-3' (SEQ ID NO.13)

[0072] T144I-R: 5'-TGTGCCCATATCaatTCCTGTATA-3' (SEQ ID NO.14)

[0073] T144M-F: 5'-TTCTATACAGGAatgGATATGGGC-3' (SEQ ID NO.15)

[0074] T144M-R: 5'-TGTGCCCATATCcatTCCTGTATA-3'(SEQ ID NO.16)

[0075] The PCR reaction system (50 μL) was: KOD enzyme (2.5 U / mL) 1.0 μL, template (5-50 ng) 1.0 μL, dNTP 4.0 μL, 10× reaction buffer 5.0 μL, upstream and downstream primers 1.0 μL each, and ddH2O was added to make up to 50 μL.

[0076] The amplification conditions of the PCR products were as follows: (1) denaturation at 94°C for 3 min, (2) denaturation at 94°C for 30 sec, (3) annealing at 54°C for 30 sec, and (4) extension at 72°C for 150 sec. Steps (2) to (4) were repeated for 10 to 15 cycles, and finally extension was performed at 72°C for 10 min. The PCR amplification products were stored at 4°C.

[0077] The PCR amplification product was detected by 1% agarose gel electrophoresis. After the detection, 0.5 μL of methylated template digestion enzyme (Dpn I) was added to 10 μL of the amplification product, and the mixture was mixed by blowing and suction with the pipette tip. The reaction was carried out at 37°C for 1 hour. The amplification product treated with Dpn I was transformed into Escherichia coli BL21 (DE3). The transformation product was spread on LB solid medium and cultured at 37°C for 8-10 hours. Five transformants were picked from the LB solid medium and inoculated into LB liquid medium for culture. After culturing at 37°C for 10 hours, the plasmid was extracted and the extracted plasmid was verified by enzyme digestion (the verification results are shown in Figure 1 and Figure 2 ) and sequencing verification. If the verification is correct, the recombinant plasmids pET28a-QtPheDH-1 to recombinant plasmids pET28a-QtPheDH-4.4 containing the encoding phenylalanine dehydrogenase mutants M1 to M4.4, and the recombinant bacteria E. coli BL21 / pET28a-QtPheDH-1 to recombinant bacteria E. coli BL21 / pET28a-QtPheDH-4.4 containing the encoding phenylalanine dehydrogenase mutants M1 to M4.4, respectively, are obtained.

[0078] The obtained recombinant bacteria E. coli BL21 / pET28a-QtPheDH and recombinant bacteria E. coli BL21 / pET28a-QtPheDH-1 to recombinant bacteria E. coli BL21 / pET28a-QtPheDH-4.4 were respectively spread on LB solid culture medium, cultured at 37°C for 8-10 hours to obtain single colonies; single colonies were picked and inoculated into LB liquid culture medium, cultured at 37°C for 12-14 hours to obtain seed solution; the seed solution was inoculated into LB liquid culture medium at an inoculation rate of 2% (v / v), and cultured at 37°C and 200rpm until OD 600 After reaching 0.8, IPTG with a final concentration of 0.2 mM was added to the fermentation broth, and the induction culture was continued at 25°C for 8 hours to obtain a fermentation broth; the fermentation broth was centrifuged at 4°C and 8000 rpm for 10 minutes, and the cells were collected; the collected cells were suspended in potassium phosphate buffer (100 mmol / L, pH 7.0) and ultrasonically disrupted, and the cell disruption supernatants containing wild-type phenylalanine dehydrogenase and phenylalanine dehydrogenase mutants M1-M4.4 were collected.

[0079] The obtained cell disruption supernatant was purified using an affinity column HisTrap FF crude (nickel column), and the purification process was as follows: first, the nickel column was equilibrated with buffer A (20 mmol / L sodium phosphate, 500 mmol / L NaCl, 20 mmol / L imidazole, pH 7.4), and the cell disruption supernatant obtained in Example 1 was passed through the nickel column, and buffer A was continued to be used to elute the protein not bound to the nickel column. After the breakthrough peak was exhausted, gradient elution was performed from buffer A to buffer B (20 mmol / L sodium phosphate, 500 mmol / L NaCl, 500 mmol / L imidazole, pH 7.4) to elute the recombinant protein bound to the nickel column, and the pure enzyme solution of wild-type phenylalanine dehydrogenase and phenylalanine dehydrogenase mutants M1-M4.4 was obtained.

[0080] The pure enzyme solution of the obtained phenylalanine dehydrogenase mutant M1 was subjected to SDS-PAGE analysis. The analysis results are shown in Figure 3 The lanes are Marker, flow-through, 50mM, 100mM, 150mM, 200mM, 250mM, and 300mM imidazole collection solutions. Figure 3 It can be seen that the pure enzyme solution of phenylalanine dehydrogenase mutant M1 shows a single band at about 45 kDa, and there are fewer impurities, indicating that the nickel column purification effect is good. The protein purification and analysis of other mutants were carried out in the same way.

[0081] Example 2: Kinetic parameters of phenylalanine dehydrogenase mutants and determination of relative specific activity of naphthyl α-keto acid substrates

[0082] The wild-type phenylalanine dehydrogenase and the phenylalanine dehydrogenase mutants M1-M4.4 obtained in Example 1 were selected, and 2-(naphthalene-1-yl)-2-oxoacetic acid at a concentration of 0.1-50 mM was used as a substrate to measure the reductive amination activity of the wild-type phenylalanine dehydrogenase and the phenylalanine dehydrogenase mutants M1-M4.4 obtained in Example 1. The data were fitted using the nonlinear regression method in Graph PadPrism 7.0 software to obtain the K values ​​of the Michaelis-Menten equation. m value, and then calculate K cat and K cat / K m The calculation results are shown in Table 2. cat The calculation formula of K is: cat =V max ·M / 1; where M is the molecular weight of the enzyme in kDa.

[0083] Table 2 Kinetic parameters of wild-type phenylalanine dehydrogenase and phenylalanine dehydrogenase mutants M1-M4.4

[0084]

[0085] As shown in Table 2, the wild-type phenylalanine dehydrogenase and the single mutation (M1) have no catalytic activity for the substrate 2-(naphthalene-1-yl)-2-oxoacetic acid, and asymmetric amination activity is generated starting from the mutant M2.1. The double mutations M2.1 and M2.2 have similar catalytic efficiencies. Among the triple mutations, the catalytic efficiency of the mutant M3.4 is about 4 times higher than that of the double mutation, and M3.1, M3.3, M3.5, and M3.6 have similar catalytic efficiencies, which are about 2 times higher than those of the double mutation. Among the quadruple mutations, M4.1, M4.3, and M4.4 have similar catalytic efficiencies, which are about 4 times higher than those of the double mutation. Mutant M4.2 exhibits the highest catalytic efficiency, which is about 8 times the catalytic efficiency of the double mutation.

[0086] The relative specific activities of the wild-type phenylalanine dehydrogenase obtained in Example 1 and the phenylalanine dehydrogenase mutants M1-M4.4 in asymmetric reductive amination of α-keto acids 2-(naphthalene-1-yl)-2-oxoacetic acid, 2-(naphthalene-2-yl)-2-oxoacetic acid, 3-(naphthalene-1-yl)-2-oxopropionic acid, and 3-(naphthalene-2-yl)-2-oxopropionic acid to produce non-natural amino acids were detected. The test results are shown in Table 3.

[0087] Table 3 Relative specific activities of wild-type phenylalanine dehydrogenase and phenylalanine dehydrogenase mutants M1-M4.4 in reductive amination of naphthyl-containing α-keto acid substrates

[0088]

[0089] As shown in Table 3, the wild-type phenylalanine dehydrogenase has no catalytic activity for 2-(naphthalene-1-yl)-2-oxoacetic acid, and has very low catalytic activity for 2-(naphthalene-2-yl)-2-oxoacetic acid. For the substrate 2-(naphthalene-1-yl)-2-oxoacetic acid, all phenylalanine dehydrogenase mutants show an improvement in catalytic specific activity compared to the wild type, starting from the double mutation, catalytic activity begins to be generated, the relative activity of the triple mutation is about 2 times that of the double mutation, the quadruple mutation M4.2 shows the highest catalytic amination activity, and the catalytic activity of the other quadruple mutants is about 3 times that of the double mutant. For the substrate 2-(naphthalene-2-yl)-2-oxoacetic acid, all phenylalanine dehydrogenase mutants showed an improvement in catalytic specific activity compared to the wild type. A single mutation can increase the catalytic amination activity by about 4 times, and the double mutation M2.1 has increased the catalytic amination activity by 6 times. The superposition of the triple mutations M3.2 and M3.4 can increase the catalytic amination activity by about 9 times. Unlike 2-(naphthalene-1-yl)-2-oxoacetic acid, the quadruple mutation M4.1 showed the highest catalytic amination activity.

[0090] Phenylalanine dehydrogenase mutants M1-M4.4 are more inclined to the sterically hindered, rigid, short-chain α-keto acid substrates 2-(naphthalene-1-yl)-2-oxoacetic acid and 2-(naphthalene-2-yl)-2-oxoacetic acid, but are not conducive to the reductive amination of the long-chain 3-(naphthalene-1-yl)-2-oxopropionic acid and 3-(naphthalene-2-yl)-2-oxopropionic acid substrates. Among all the phenylalanine mutants, the triple mutants M3.1 and M3.4 can catalyze the four different types of substrates, greatly broadening the catalytic substrate spectrum of phenylalanine dehydrogenase, and have high application value and research value.

[0091] Example 3: Conversion efficiency of asymmetric amination of 2-(naphthalene-1-yl)-2-oxoacetic acid by phenylalanine dehydrogenase mutants

[0092] The cyclohexanone monooxygenase mutant M4.2 obtained in Example 1 was selected and added to 2M NH4Cl / NH4OH buffer (pH 9.0) containing 25mM, 50mM, 75mM, and 100mM of the α-keto acid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid at an addition amount of 5g / L, and the reaction was carried out at 30°C, pH 9.0, and 200rpm for 10h to obtain a reaction solution; in addition to the α-keto acid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid, the NH4Cl / NH4OH buffer also contained a coenzyme NAD with a concentration of 0.5mM. + , 120 mM glucose, 1.5 mM glucose dehydrogenase GDH and 5% (v / v) methanol. The conversion rate of the asymmetric reductive amination of α-keto acid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid by the phenylalanine dehydrogenase mutant M4.2 was detected at different reaction times. The detection results are shown in Table 4.

[0093] Table 4 Conversion rate of phenylalanine dehydrogenase mutant M4.2 in asymmetric reductive amination of α-keto acid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid at different concentrations

[0094]

[0095]

[0096] The cyclohexanone monooxygenase mutant M4.2 obtained in Example 1 was selected and added to a 2M NH4Cl / NH4OH buffer (pH 9.0) containing 100mM α-ketoacid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid at an addition amount of 5g / L, 10g / L, 15g / L, and 20g / L, respectively, and reacted at 30°C, pH 9.0, and 200rpm for 10h to obtain a reaction solution; in addition to the α-ketoacid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid, the NH4Cl / NH4OH buffer also contained a coenzyme NAD with a concentration of 0.5mM. + , 120 mM glucose, 1.5 mM glucose dehydrogenase GDH and 5% (v / v) methanol. The conversion rate of the asymmetric reductive amination of α-keto acid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid by the phenylalanine dehydrogenase mutant M4.2 was detected at different reaction times. The detection results are shown in Table 5.

[0097] Table 5 Conversion rate of asymmetric reductive amination of α-keto acid substrate 2-(naphthalene-1-yl)-2-oxoacetic acid by different phenylalanine dehydrogenase mutant M4.2 enzyme addition

[0098]

[0099] As shown in Table 5, under the condition that the enzyme dosage of phenylalanine dehydrogenase mutant M4.2 is 5g / L, 25mM and 50mM substrates can be completely converted in 10h, and as the substrate concentration increases, the reaction tends to stagnate after 1h. Finally, under the substrate concentration of 75mM, the conversion rate is maintained at about 5%, and under the substrate concentration of 100mM, the conversion rate is maintained at about 1.5%. As shown in Table 5, when the substrate dosage is 100mM, the enzyme dosages of 5g / L, 15g / L, and 20g / L cannot effectively convert 2-(naphthalene-1-yl)-2-oxoacetic acid. Only when the enzyme dosage is increased to 25g / L, the 100mM substrate can be rapidly converted.

[0100] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A phenylalanine dehydrogenase mutant, characterized in that: The phenylalanine dehydrogenase mutant is prepared by subjecting the amino acid sequence of the starting sequence shown in SEQ ID NO.1 to any of the following modifications: (1) Valine at position 329 mutated to glycine, and serine at position 176 mutated to glycine or alanine; (2) The valine at position 329 mutates to glycine, the serine at position 176 mutates to glycine, and the threonine at position 144 mutates to valine, leucine, isoleucine, or methionine; (3) The valine at position 329 mutated to glycine, the serine at position 176 mutated to glycine, the leucine at position 326 mutated to cysteine, and the threonine at position 144 mutated to methionine or isoleucine.

2. A gene encoding the phenylalanine dehydrogenase mutant according to claim 1.

3. An expression vector comprising the gene according to claim 2.

4. The expression vector according to claim 3, characterized in that The expression vector is pET-28a(+) plasmid, pET-28b(+) plasmid or pET-20b(+) plasmid. A host cell comprising the phenylalanine dehydrogenase mutant according to claim 1, wherein the host cell is a non-plant cell or an animal cell.

6. Use of the phenylalanine dehydrogenase mutant according to claim 1, the gene according to claim 2, the expression vector according to claim 3 or the host cell according to claim 5 in producing L-unnatural amino acids.

7. A method for producing an L-unnatural amino acid, characterized in that The method comprises the following steps: adding the phenylalanine dehydrogenase mutant according to claim 1 or an expression system containing the mutant to a reaction system containing a substrate for reaction, wherein the substrate is 2-(naphthalene-1-yl)-2-oxoacetic acid or 2-(naphthalene-2-yl)-2-oxoacetic acid.

8. The method according to claim 7, characterized in that: The reaction system contains coenzymes and a coenzyme circulation system.

9. The method according to claim 8, characterized in that: The coenzyme circulation system is any one of D-glucose and glucose dehydrogenase, phosphite and phosphite dehydrogenase, formate and formate dehydrogenase, lactate and lactate dehydrogenase, glycerol and glycerol dehydrogenase.